ScreenCell® logo
Quote

Evaluation of Circulating Tumor Cells (CTCs) by the ScreenCell® device in breast cancer: validation of biomarkers

  • Last updated:17 June 2025

General information about the study

Type of cancer:

  • Metastatic breast cancer

Type of study:

  • Proof of concept

Status of the study:

  • Completed

Promoter:

  • ScreenCell®

Investigative center:

  • Laboratoire Dr Kahia Tani

Summary of the study

–

Main objective(s):

To demonstrate that the ScreenCell® CYTO device is capable of isolating circulating tumor cells (CTCs) in metastatic breast cancer and counting these cells based on the expression of specific biomarkers. Two biomarker cocktails will be compared:

1) Conventional cocktails: EpCAM + Cytokeratin + CD45
2) ScreenCell cocktail: MARCKSL1, SLC9A3R1, and RHOD

Study references

Official title:

  • Evaluation des Cellules Tumorales Circulantes (CTC) par le dispositif ScreenCell® dans le cancer du sein : validation de biomarqueurs

NCT Number:

  • -

Link :

  • -

Study Contact.s

  • ScreenCell®
  • Jessica Groult
  • jgroult@screencell.com